Skip to Main Content

Paper Details

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
Br J Haematol
53
2017
B, B-NHL, B-cell non-Hodgkin lymphoma, CD20 monoclonal antibody, CLL, NHL, Patients, Ublituximab, anaemia, anti-CD20 monoclonal antibody, chronic lymphocytic, chronic lymphocytic leukaemia, diarrhoea, fatigue, leukaemia, neutropenia, patient, patients, pyrexia, rituximab, tumour, ublituximab
Author NameAffiliation
Changchun DengCenter for Lymphoid Malignancies, Columbia University Medical Center
John G KuhnUniversity of Texas Health Science Center at San Antonio
  • 1 - 2

Datasets

Release 1.2